Jacobs Levy Equity Management
INBX icon

Jacobs Levy Equity Management’s Inhibrx INBX Stock Holding History

Jacobs Levy Equity Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,329
Closed -$762K – 1013
2026
Q1 		$762K Buy
11,329
+1,188
+12% +$88.1K ﹤0.01% 759
2025
Q4 		$801K Sell
10,141
-3,578
-26% -$244K ﹤0.01% 722
2025
Q3 		$462K Buy
+13,719
New +$338K ﹤0.01% 830
2024
Q4 		– Sell
-20,469
Closed -$321K – 993
2024
Q3 		$321K Buy
+20,469
New +$288K ﹤0.01% 877

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jacobs Levy Equity Management's INBX Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 11,329 shares — an estimated $762K sold.

Jacobs Levy Equity Management first reported a position in INBX in Q3 2024 and held it in 4 quarters. The position peaked at $801K in Q4 2025. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 11,329 Inhibrx shares in Q2 2026, an estimated $762K.
  • Jacobs Levy Equity Management first reported a position in Inhibrx in Q3 2024 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Inhibrx position peaked at $801K in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.